Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AstraZeneca | 9.18% | $91.28M | $324.77B | 32.79% | 80 Outperform | |
| HSBC Holdings | 8.78% | $87.29M | £218.16B | 44.94% | 80 Outperform | |
| Shell (UK) | 6.67% | $66.35M | £162.01B | 9.05% | 73 Outperform | |
| Unilever | 4.50% | $44.76M | £118.04B | 7.61% | 72 Outperform | |
| Rolls-Royce Holdings | 4.42% | $44.00M | £109.32B | 121.53% | 71 Outperform | |
| British American Tobacco | 3.64% | $36.20M | £93.76B | 43.37% | 71 Outperform | |
| GlaxoSmithKline | 3.57% | $35.50M | £90.34B | 57.77% | 77 Outperform | |
| Rio Tinto | 3.01% | $29.95M | £120.85B | 46.72% | 82 Outperform | |
| BP p.l.c. | 2.90% | $28.84M | £70.79B | 1.34% | 71 Outperform | |
| Barclays | 2.66% | $26.49M | £65.36B | 58.86% | 78 Outperform |